News

Scienture Holdings Launches FDA-Approved Arbli Oral Suspension

Scienture Holdings Launches FDA-Approved Arbli Oral Suspension

Scienture Holdings Introduces FDA Patent Listing for Arbli

Scienture Holdings, Inc. (NASDAQ: SCNX), a prominent player in the pharmaceutical sector, has recently reached a significant regulatory milestone. The U.S. Food and Drug Administration (FDA) has officially listed their innovative product, Arbli™, an oral suspension of losartan potassium at a concentration of 10mg/mL, under its Approved Drug Products with Therapeutic Equivalence Evaluations, famously known as the Orange Book.

Understanding Arbli and Its Implications

The patents involved, U.S. Patent Nos. 11890273 and 12156869, are projected to remain valid until October 2041. The patents, both titled “Losartan Liquid Formulations and Methods of Use,” emphasize stable, liquid formulations of losartan, ensuring effective treatment for patients in need. This listing not only solidifies Scienture's intellectual property rights but positions them for competitive advantage under the Hatch-Waxman Act, which aims to streamline drug approval and patent protections.

The Unique Offering of Arbli

Arbli™ is uniquely designed for patients experiencing hypertension, particularly those over six years old. It is effective for reducing stroke risk in hypertension cases with left ventricular hypertrophy, as well as treating diabetic nephropathy. This product stands out as the first FDA-approved ready-to-use oral liquid version of losartan available in the U.S. market.

Advantages of the Arbli Formulation

This proprietary formulation offers a tailored solution for patients who require an oral liquid form of losartan. Unlike existing options that are available only as solids, Arbli™ facilitates an easier, safer dosage method for those who have difficulties with solid medications. Its FDA-approved status guarantees quality, ensuring patients can trust in effective treatment.

Moreover, this oral solution eliminates the risks related to the compounding of losartan tablets, which may lead to inconsistencies and dosing inaccuracies. Arbli™ not only simplifies administration with its ready-to-use format but also boasts a reduced dosage volume and stability at room temperature.

The Market Potential for Arbli

Recent data reveals that losartan sales in the U.S. are substantial, with estimates around $276 million annually and a prescription volume soaring over 69 million transactions. This substantial market potential makes Arbli™ a game-changer in the treatment of hypertension, catering specifically to patients who prefer liquid medication.

Dr. Shankar Hariharan, President of Scienture, expressed enthusiasm regarding this milestone, stating, “This Orange Book listing reaffirms our commitment to elevating healthcare standards by providing accessible, high-quality treatments.”

The Significance of Patent Listings

The patent listings for Arbli™ not only enhance Scienture's intellectual property framework but also clarify their commercial strategies within the U.S. pharmaceutical market. Dr. Narasimhan Mani, another key figure at Scienture, emphasized, “It reflects our focus on patient-centric innovation and is pivotal in our ambition to deliver impactful therapies to those in need.”

The Arbli Characteristics

Arbli™ is marketed in a 165 mL bottle, flavored with peppermint, and importantly, does not require refrigeration. Its approval allows for an 18-month shelf life under appropriate storage conditions, with plans to extend this duration pending further stability tests with data submitted to the FDA.

Indications and Important Safety Information

As an angiotensin II receptor blocker (ARB), Arbli™ is indicated for:

  • Treating hypertension in adults and children over six years old.
  • Reducing stroke risk in patients with hypertension and left ventricular hypertrophy.
  • Addressing diabetic nephropathy in type 2 diabetes patients with specific conditions.

Safety alerts emphasize that Arbli™ should not be used by pregnant women, as it poses significant risks to fetal health. It is crucial for patients and caregivers to consult healthcare professionals and report any adverse effects to the FDA.

A Closer Look at Hypertension

Hypertension remains a critical health issue, affecting nearly half of all adults in the United States. Characterized by elevated blood pressure, this condition raises the risk of heart diseases and strokes—two leading causes of death. Factors contributing to hypertension include age, obesity, inactivity, and dietary choices.

The Role of Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) serves as the parent company of Scienture, LLC, dedicated to developing novel pharmaceutical solutions that enhance patient and healthcare experience. With a diverse portfolio addressing various therapeutic needs, Scienture is driven by a commitment to innovation and improving health outcomes. For more details, visit www.scientureholdings.com.

Frequently Asked Questions

What is Arbli™?

Arbli™ is an oral suspension of losartan potassium, approved by the FDA for treating hypertension.

How does Arbli™ differ from traditional losartan medications?

Unlike conventional losartan treatments available only in solid form, Arbli™ is a ready-to-use liquid that eases administration and enhances accuracy in dosing.

What are the primary uses of Arbli™?

Arbli™ is indicated for treating hypertension, reducing stroke risk for specific hypertensive patients, and managing diabetic nephropathy in some patients.

What safety precautions should be taken with Arbli™?

Arbli™ should not be administered during pregnancy due to potential risks to fetal health, and it should not be combined with specific medications in certain patient populations.

How can patients obtain more information about Arbli™?

Patients should consult their healthcare providers for more information, or they can reach out directly to Scienture Holdings, Inc. for assistance.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Royce Global Trust's Discount Is Still the Whole Debate

Updated Category News Views 106

A $3.03 gap is staring investors right in the face. As of October 31, 2026, Royce Global Trust carried a net asset value of $17.51 per share while the market price sat at $14.48. That works out to roughly a 17.3% discount to NAV, and with a closed-end fund, that discount is not some footnote shoved under the table. It is a major part of the return story, good or bad. The...

Continue Reading
Movement Elevates a Longtime Insider as Its New CEO

Updated Category News Views 87

Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...

Continue Reading
FFR Adds Academic and Commercial Muscle to Its Board

Updated Category News Views 65

Robotics boards can get crowded with lofty nouns fast, and FFR just added another one with some real-world connective tissue behind it. Carolyn Kissane, associate dean at NYU's Center for Global Affairs, has joined as an independent director. The appointment is not a product launch, a contract, or revenue. It is a governance move. Still, in a business trying to weld...

Continue Reading
L’Oréal’s Women of Worth Shows Why Brand Patience Matters

Updated Category News Views 120

Twenty-one years is a long time to keep a corporate promise from turning into wallpaper. L’Oréal Paris gathered its 2026 Women of Worth class at the Ebell in Los Angeles on November 18, recognizing 10 nonprofit leaders working on problems that do not yield to a glitzy evening or a tidy slogan. That distinction matters. Cancer survivorship, trafficking prevention,...

Continue Reading
Hope Charities Makes Care Funding Easier to Track Online

Updated Category News Views 72

A treatment bill can wreck a household long before a diagnosis does. That is the uncomfortable reality behind Hope Charities' new Access to Care website, a centralized resource meant to show people in the bleeding disorders community when diagnosis-specific charitable assistance funds are available. This is not flashy technology, nor should it be treated like some grand...

Continue Reading
PTC Pushes Deeper Into Federal Product Development

Updated Category News Views 82

Federal engineering software is a miserable place to show up late, and PTC is plainly trying not to. Its November 19, 2026 expansion brings Windchill+ onto Microsoft Azure Government through PTC Cloud Services and introduces Onshape Government Federal for teams handling Controlled Unclassified Information. This is not a glamorous product refresh. It is a bid to remove the...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 223

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 57

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 106

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 8

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading

Top 5 Most Recently Viewed Articles

Euroseas Ltd. Achieves Strong Financial Results and Growth

Updated Category News Views 141

Overview of Euroseas Ltd. Euroseas Ltd. operates as a leader in the container shipping sector, primarily focused on providing efficient seaborne transportation for containerized cargo. The company has established a strong reputation for operational excellence and commitment to sustainable practices within its fleet management. Financial Performance Highlights In a recent...

Continue Reading
Market Dynamics Shifting with Focus on Inflation Trends

Updated Category News Views 180

Market Performance and Economic Insights As we dive into today's economic landscape, U.S. stocks have reached new heights while the effects of a recent hurricane are fading. With key inflation data set to be released soon, analysts are closely monitoring market responses and the implications for future Federal Reserve policy. The recent performance of U.S. stocks...

Continue Reading
Strategic Moves: Nordson EVP Acquires Over $250K in Stock

Updated Category News Views 214

Nordson EVP Makes Significant Stock Investment Recently, a notable movement was observed in the stock holdings of Nordson, specifically by its Executive Vice President, Daniel Roy Hopgood. According to a recent SEC filing, Hopgood made a considerable insider purchase worth $251,885, acquiring 1,201 shares of Nordson. Insights into the Insider Transaction This transaction,...

Continue Reading
Rising Pet Poisoning Calls Due to Antidepressants and ADHD Drugs

Updated Category News Views 102

Back between 2019 and 2022, we saw an insane rise in calls to pet poison hotlines—an 84.9% spike related to antidepressants and antianxiety drugs. You know that’s serious business when folks are dialing in about their furry friends getting into the pills meant for human mental health. The numbers don’t lie; as people got more open about mental health issues, it...

Continue Reading
Humacyte, Inc. Investors: Class Action Lawsuit Update

Updated Category News Views 330

Understanding the Class Action Lawsuit Against Humacyte, Inc. Many investors are becoming increasingly aware of the class action lawsuit against Humacyte, Inc. (NASDAQ: HUMA). The firm leading this charge, Pomerantz LLP, has filed this significant case to address potential securities fraud related to the company's operations and communications. This legal action has...

Continue Reading